Introduction
In patients with RA mortality is higher in comparison with the general population, and standardized mortality ratio (SMR) ranges from 1.3 to 3.0 [1] . The leading cause of morbidity and mortality is cardiovascular disease (CVD) [2, 3] , and the cardiovascular (CV) events occur approximately a decade earlier in patients with RA than in the general population [4, 5] . Increased risks are found when analysed by atherosclerotic events, causes of death or measures of atherosclerosis, such as intimamedia thickness (IMT), carotid artery plaque or coronary artery calcification. A recent meta-analysis has shown that despite the milder course of RA disease over past decades, the magnitude of overall CVD-dependent mortality is still associated with a 60% increased risk of CVD death [6] . Thus, targeting a reduction in CV mortality should still be considered a major issue in treatment of RA patients. This task is hampered by the failure of traditional and inflammatory/ disease-related risk factors to fully account for the elevated CVD risk [7, 8] . Therefore, diagnostic instruments and biomarkers capable of improving CV risk assessment are currently warranted.
A diagnostic tool to detect premature atherosclerosis is carotid US. Carotid IMT (cIMT) of the common carotid artery (CCA) is a useful surrogate indicator of the early subclinical stage of macro-vascular atherosclerosis disease [9] . cIMT has been found to be increased as early as within 12 months of symptom onset of RA [10] and the use of carotid US as a predictor of CV events in RA has been supported [11] .
Among the traditional risk factors disorders in lipid metabolism have been postulated to be central to the development of atherosclerosis. Mounting evidence addresses the importance of apolipoproteins as powerful lipid-related predictors of CVD risk in the general population [12] , but the role of apolipoproteins in RA disease is uncertain. Plasma levels of oxidized low-density lipoprotein (oxLDL) have also been described as a promising prognostic marker for future CVD [13] ; besides, increased oxLDL levels have been associated with more active RA disease [14] .
Further, both innate and adaptive immunity links multiple risk factors for atherosclerosis with altered arterial biology [15] . Antibodies against phosphorylcholine (anti-PC), especially of the immunoglobulin M (IgM) subclass, could play a protective role in atherogenesis and chronic inflammation [16] . Recently, an independent association of carotid plaque occurrence with low anti-PC IgM levels has been demonstrated in patients with SLE [17] .
Previous studies on the contribution of CV risk factors to atherosclerosis in patients with RA are mostly of cross-sectional design missing variability of systemic inflammation overtime, restricted to females or including only patients with highly different disease duration. Thus, there is a need for studies involving patient populations followed prospectively since disease onset. In the present study we examined the associations of established CVD risk factors, inflammatory/RA disease-related and novel biomarkers (apolipoproteins, oxLDL and anti-PC) at baseline and throughout the first 5 years of RA disease with cIMT and carotid plaque presence in a one-centre longitudinal cohort study of patients with early RA.
Patients and methods

Patients
The study population was recruited from Karolinska University Hospital, Huddinge, which is one part of the six-centre BARFOT (Better Anti-Rheumatic FarmacOTherapy) study designed to investigate clinical and therapeutic aspects of early RA [18] . Briefly, at inclusion the patients had a RA diagnosis according to the ACR criteria [19] and a disease duration of <1 year. After baseline evaluation, regular follow-up assessments according to the study protocol were conducted. The patients had been treated with DMARDs in accordance with the recommended treatment strategy in Sweden.
The recruitment to this study took place between June 2000 and March 2004. We identified patients who had been followed for 5 years since RA diagnosis and were aged <70 years at BARFOT inclusion. Of 203 eligible patients, 114 patients were available and willing to undergo high-resolution B-mode ultrasonography of the carotids. Thus, 89 individuals were not included because of unwillingness or because they had moved. These non-participants did not differ from the patients included in the study in age, sex or baseline 28-joint DAS (DAS-28) and functional disability. All study participants provided written informed consent. The study was approved by the Karolinska University Hospital Ethics Committee and was performed in accordance with the Declaration of Helsinki.
Disease assessments
Clinical and routine laboratory examinations were conducted at inclusion and after 3, 6, 12, 24 and 60 months. Disease activity was measured by the composite index DAS-28, calculated on 28 joints [20] . Functional disability was assessed using the Swedish version of the Stanford HAQ [21] . Radiographic changes of hand, wrist and/or feet at baseline were defined according to ACR criteria [19] .
At BARFOT inclusion, a patient was defined as having a pre-existing CVD if angina pectoris, acute myocardial infarction (AMI), coronary surgery or ischaemic stroke were diagnosed by a physician according to current criteria and documented in patients' medical history. Hypertension was considered whether a systolic blood pressure 5140 mmHg and/or diastolic 590 mmHg and/ or prescription of anti-hypertensive drug. Diabetes mellitus was defined as a history of diabetes and/or prescription of anti-diabetic medication. Smoking status was characterized as daily ever smoking (current or past) or never smoking.
Laboratory tests
Venous blood samples were aliquoted immediately, and ESR, CRP and RF were analysed with routine methods. CRP was measured by a non-high-sensitive assay and low levels were reported as <10 mg/l. RF was measured by agglutination test where a positive titre was >1/20.
Moreover, non-fasting blood samples were collected for storage (À70 C) in a bio bank for the following analyses.
Apolipoprotein A1 (apoA1) and B (apoB) were determined with Synchrone LX from Beckman AB by immunoturbidimetry. Dyslipidaemia was defined as serum apoA1 <1.25 g/l for women or <1.15 g/l for men, apoB 50.9 g/l for both genders, apoB/apoA1 ratio 50.6 for women or 50.7 for men [22] and/or lipid-lowering drug treatment. For apoA1 measurements, intra-and inter-assay coefficients of variation were 1.5 and 3.9%, respectively, total precision was 3.5%. For apoB measurements, respective coefficients of variation were 0.9 and 2.8%, and total precision 3.6%.
oxLDL and anti-PC IgM oxLDL and anti-PC IgM were determined by ELISA (Mercodia AB, Uppsala Sweden; and Athera CVDefine kit, Athera Biotechnologies AB) as described [23, 24] . IgM anti-PC and oxLDL levels were expressed as arbitrary units. Population-based reference for oxLDL (obtained from 149 ambulatory, randomly selected individuals in the Stockholm area, Sweden) is mean 61, range 26117 U/l. IgM anti-PC measuring range was from 6.25 to 100 U/ml; samples giving absorbance >100 U/ml were diluted as appropriate and re-assayed. Intra-and inter-assay coefficients of variation for IgM anti-PC were 5.2 and 1.1%, and for oxLDL 6.2 and 4.0%, respectively.
Assessment of carotid intimamedia measurements
The right and left carotid arteries were examined with a duplex scanner (Aspen, Acuson, Mountain View, CA, USA) using a 7 MHz linear array transducer as described earlier [25] . The far wall of the CCA, 0.51.0 cm proximal to the beginning of the carotid bulb, was used for measurements of the cIMT. The cIMT was defined as the distance between the leading edge of the lumenintima echo and the leading edge of the mediaadventitia echo and was measured in the region free of atherosclerotic plaques. The examinations were videotaped for subsequent analyses by a computer system with automated tracing of echo interfaces and measurements of distances between the wall echoes within a 10-mm long section of CCA in late diastole, defined by a simultaneous electrocardiographic recording. For right and left CCA, the mean values of the cIMT within the 10-mm long section were estimated. Then, the mean cIMT [(right + left)/2] was calculated. The intra-reader coefficient of variation for cIMT was 3.2%, based on 25 re-read images. Carotid plaque was defined as a localized intimamedia thickening of >1 mm and at least a 100% increase in thickness compared with adjacent wall segments. Plaque was screened for in the common, internal and external carotids. Plaque occurrence was scored as the absence of plaque, the presence of unilateral plaque and the presence of bilateral plaque. The carotid measurements were made by two certified ultrasonographers (R.A. and M.R.). In order to investigate the association between study outcomes and different risk factors, we applied a series of univariate regression analyses. Then, we constructed multivariate regression models (linear for continuous outcome and ordinal logistic regression for categorical outcome) to detect a combination of significant established factors, and then, to this base model we added studied factors one by one if these variables' P-values were <0.10 in univariate analyses.
To evaluate the association of changes over time in tested variables with the study outcomes, we applied mixed linear modelling for continuous variables and generalized estimating equations (GEEs) for dichotomized variables. Time was modelled as a categorical variable because of unequally spaced time intervals. Mixed linear modelling is a longitudinal extension of linear regression analysis, and GEE of logistic regression. The best fit covariance model was chosen according to the correlation matrix and the smaller value of the Akaike's or Quasi likelihood information criteria (AIC or QIC). Log transformation was performed if required to fulfil assumption of normality. The level of significance was chosen to be P < 0.05.
Results
Patients' characteristics as well as treatment against RA at inclusion, throughout the study and after 5 years of followup are presented in Tables 1 and 2 . Thus, 7 (6.1%) patients had a history of pre-existing CVD, 77 (67.5%) patients had been ever smokers (past or current) and only two of the patients were treated with lipid-lowering drugs at RA diagnosis. Further, at that time point the patients had high disease activity that was reduced significantly after 5 years. All patients had started treatment with DMARDs at diagnosis, and most patients were still on DMARDs at the 5-year control. There had been changes in DMARD use during the study period, from mostly SSZ towards MTX, combination therapy and biologics. Further, the use of glucocorticoids had decreased throughout the study period. Fewer than 10 patients had started statin therapy close to the end of the observation period.
The apolipoproteins had not changed at the 5-year assessment compared with baseline (P > 0.05), whereas the oxLDL levels had increased and anti-PC decreased www.rheumatology.oxfordjournals.org (P = 0.000 and 0.001, respectively). The carotid US measures at the 5-year assessment are given in Table 3 . Mean cIMT was 0.67, IQR 0.600.77 mm. Eighty (70.2%) patients had carotid plaque at one or both sides. On the whole, cIMT differed between those without plaque, unilateral or bilateral plaque (P = 0.000). Besides, cIMT was higher in cases with unilateral plaque presence vs no plaque (P = 0.031), and it was higher in cases with bilateral plaque vs unilateral plaque (P = 0.017).
Primary regression analyses
Unadjusted regression analyses showed that age, male gender, smoking (ever vs never) and a history of preexisting CVD/hypertension/diabetes mellitus were positively associated with cIMT (P < 0.001), and with plaque presence (P < 0.01), after 5 years of follow-up. Baseline apolipoprotein levels did not prove any association with carotid measurements after 5 years.
Among inflammatory/disease-related factors, cumulative dose of MTX showed a negative association with cIMT (P = 0.038), while the presence of rheumatoid nodules at baseline was positively associated with carotid plaque (P = 0.001), after the follow-up. Initial levels of other disease-related factors such as ESR, DAS-28, tender or swollen joint count, as well as the presence of radiographic changes at baseline, RF or ANA positivity, the usage of anti-malarial or cumulative dose of glucocorticoids failed to show statistically significant association with the study outcomes.
Among novel factors, the lowest tertile of anti-PC at baseline (446.6 U/ml) was positively associated, while Values are mean (S.D.) or median (IQR) as appropriate, categorical as frequencies (percentages). n: number. CVD: angina pectoris, myocardial infarction, coronary surgery and stroke. Radiographic changes according to ACR criteria, erosions or unequivocal bony decalcification localized in or most marked adjacent to the involved joints on hand, wrist and/or feet radiographs. Dyslipidaemia: serum apoA1 <1.25 g/l for women or <1.15 g/l for men, apoB 50.9 g/l for both genders, apoB/apoA1 ratio 50.6 for women or 50.7 for men and/or lipid-lowering drug treatment.
the highest tertile of anti-PC at baseline (587.0 U/ml) was negatively associated with bilateral carotid plaque presence (P = 0.054 and 0.016). Multivariate regression analyses showed that only age, male gender, smoking (ever) and a history of pre-existing CVD/hypertension/diabetes mellitus had strong independent associations with cIMT (P = 0.000, 0.012, 0.000 and 0.002 respectively). Logistic regression analyses showed a positive association between bilateral carotid plaque and age (odds ratio OR 1.16, 95% CI 1.06, 1.45, P = 0.000). Then, subjects who had never smoked had lower risk of having bilateral carotid plaque compared with those who smoked currently or in the past (OR 0.51, 95% CI 0.27, 0.97, P = 0.040), independently of age and gender. Plaque presence was not significantly associated with other tested factors after adjustment for age and gender.
Longitudinal analyses
In unadjusted longitudinal analyses, positive predictors of cIMT were log apoB, apoB/apoA1 ratio and oxLDL, while log apoA1 was a negative predictor (P < 0.05). Bilateral carotid plaque presence was positively associated with log apoB, apoB/apoA1 ratio, oxLDL, CRP and low anti-PC tertile over time (P < 0.05), whereas there were trends for negative associations with log anti-PC and the high anti-PC tertile over time (P = 0.080 and 0.093).
After controlling for age, gender, smoking and a history of CVD/hypertension/diabetes, longitudinal development of log apoA1 confirmed a negative independent association with cIMT ( = À0.24, 95% CI À 0.47, À 0.02, P = 0.047), whereas log apoB/apoA1 ratio showed a positive association ( = 0.45; 95% CI 0.04, 0.85, P = 0.030); thus, the reduction in apoA1 by 2.4% (95% CI 0.1, 4.6%) or the increase in apoB/apoA1 ratio by 4.6% (95% CI 0.3, 8.9%) corresponded to an increase in cIMT of 0.1 mm. Longitudinal development of log apoB and oxLDL failed to prove a significant independent association with cIMT (P = 0.47 and 0.15).
Further, higher levels of apoB and apoB/apoA1 ratio, as well as low anti-PC tertile (439.6 U/ml) during the follow-up proved independent significant associations with carotid plaque detection after 5 years of RA disease (P = 0.002, 0.026, 0.000, respectively) (Fig. 1AC ). Higher levels of oxLDL during follow-up tended towards a positive association with plaque presence (P = 0.079) (Fig. 1D) . Concerning longitudinal development of log CRP, anti-PC or the highest tertile of anti-PC, no associations with carotid plaque detection were obtained after adjustment.
Discussion
In this prospective observational study on patients with early RA followed during the first 5 years of disease, we proved that age, male sex, ever smoking and previous CVD/hypertension/diabetes were independent predictors of cIMT and plaque presence. Further, a longitudinal approach showed an independent negative association between apoA1 levels and cIMT, whereas an unfavourable association was found for apoB/apoA1 ratio. In addition, higher levels of pro-atherogenic apolipoproteins, apoB and apoB/apoA1 ratio, and the low tertile of anti-PC during the whole follow-up were independently associated with enhanced detection of bilateral carotid plaque at the 5-year assessment.
Carotid IMT is increasingly used as a surrogate marker for atherosclerosis and as a predictor of future CV events in healthy individuals [26] . A systematic review and meta-analysis have shown that for an absolute cIMT difference of 0.1 mm the future risk of myocardial infarction increases by 1015%, and stroke risk increases by 1318% in the general population [26] . In this regard, our results suggest that even small changes in apoA1 and apoB/apoA1 ratio, by a mean of 2.4 and 4.6%, respectively, might correspond to a clinically significant influence on risk of future CVD.
In the present study, we found higher cIMT in subjects with carotid plaque compared with those without detectable plaque at a time point when disease activity was low. This association suggests that cIMT measurement reflected subclinical atherosclerosis in our patients. However, it has been questioned whether carotid measurements do indeed provide evidence of atherosclerosis www.rheumatology.oxfordjournals.org in inflammatory conditions such as RA. Thus, in a recent meta-analysis of carotid assessment in rheumatic diseases agreement between cIMT and carotid plaque was not found [27] . This discrepancy might depend on that cIMT in those with chronic inflammatory disease also measure current and possibly reversible inflammation of the vessel wall, but our patients had a low disease activity at the time of carotid measurements.
In the present cohort, the prevalence of carotid plaque was higher, 70%, than in other studies [2830] . Still, in a comparative group of patients with established RA, with a mean disease duration of 5 years, carotid plaque was detected in 65% of both RA cases and matched controls [31] . The discrepancy in plaque prevalence among studies may be related to differences in patient material, mostly RA disease duration, inflammatory activity, concomitant therapeutic agents, gender distribution, exclusion of pre-existing comorbidities as well as methodological issues, such as plaque definition and US scanning in different arterial segments. A recent study has readily demonstrated that atherosclerosis, measured by carotid US is an important predictor of both incident and multiple acute coronary syndromes in patients with RA [32] .
An important finding in the present study was that pro-atherogenic apoB and apoB/apoA1 ratio were independently associated with unfavourable carotid outcomes, while a profitable effect was associated with anti-atherogenic, anti-inflammatory apoA1. These results suggest that apolipoproteins are independent predictors of cIMT and carotid plaque in patients with RA. Current published data are insufficient to conclude whether changes in apolipoproteins, especially apoA1, mirror changes in traditional lipids, and whether apolipoproteins are more susceptible to fluctuation due to inflammatory changes, or whether apolipoproteins may be more useful for absolute CV risk estimation in patients with RA [33] . Also, it should be pointed out that at the time of the study conduction statins were under-utilized, probably partly due to generally lower lipid levels in the rheumatic condition. This important issue has recently been highlighted in a study demonstrating that the use of statins is grossly suboptimal in patients with RA in secondary care [34] .
As to oxLDL, it has been postulated to have a central role for initiation and development of atherosclerosis [35] . Furthermore, elevated oxLDL may play a role in the   FIG. 1 Association between plaque presence after 5 years of RA disease and longitudinal changes in the studied markers, (A) log apoB; (B) log apoB/apoA1 ratio; (C) lowest tertile of anti-PC; (D) log oxLDL; controlled for age, gender, smoking habits, history of CVD/hypertension/diabetes, P-value is indicated.
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transformation from stable to vulnerable, unstable plaque [36] . Also, oxLDL has pro-inflammatory and immunogenic properties and contains other oxidized products, including platelet-activating factor (PAF)-like lipids [37, 38] . Here, it would be important to underline our finding of increasing oxLDL throughout the study despite effective control of inflammation. This increase in oxLDL levels might influence both progression of atherosclerosis and RA disease per se. Meanwhile, the results of the present study were not conclusive about association between oxLDL levels and carotid US measurements.
Here, we report that low IgM anti-PC levels longitudinally had an unfavourable association with plaque presence at the end of the observation period. This finding is in line with our previous studies where low anti-PC levels have been predictive for increased risk of CVD including stroke and myocardial infarction [24, 3941] .
Natural antibodies against PC (anti-PC) can react to PC on bacteria, oxLDL and apoptotic cells, but not to those on unoxidized phospholipids or viable cells [42] . Since oxidation-specific epitopes are abundantly present in atherosclerotic disease, anti-PC may inhibit uptake of pro-atherogenic oxLDL in macrophages by scavenger receptors; thus, anti-PC may have a role in clearance of atherosclerotic plaques [40, 43] . In a mouse model, both active and passive transfer of anti-PC could ameliorate atherosclerosis development [44, 45] .
IgM anti-PC could play a role in chronic inflammation by inhibiting pro-inflammatory effects mediated by PAF-like lipids generated during LDL oxidation [46] . In a casecontrol study in SLE, an association has been demonstrated between the lowest quartile of anti-PC and SLE disease activity, while other antibodies were increased [46] . In a recent study in RA patients, we found that low levels of IgM anti-PC were characteristic of non-responders to biologics (S. Ajeganova et al. 2011, data not published). We have proposed that low anti-PC levels may characterize an immune-deficient state of depressed anti-inflammatory capacity, and that low anti-PC levels could distinguish ongoing inflammation. In this regard, it is worth noting that in the present study anti-PC levels significantly decreased during the follow-up despite amelioration of inflammation measured by conventional methods.
In the present study, neither initial levels nor longitudinal development of tested inflammatory markers revealed associations with carotid measures, after full adjustment. These negative findings might seem to contradict the hypothesis of a correlation between inflammation and progressive atherosclerosis [15] . Still, in RA disease under ongoing treatment the disease activity seems to influence mostly plaque vulnerability, not cIMT measurement or plaque presence per se [47] . Our results suggest, however, that influence of traditional risk factors, age and smoking status especially, is strong and might dissemble the effect of other factors and concomitant anti-rheumatic therapies.
To the best of our knowledge, this is the first study using a longitudinal approach to study lipids' contribution to carotid atherosclerosis, which provides additional information about significance of changes in apolipoproteins over time. At the same time, this approach may be less suitable for estimation of the importance of other biomarkers, e.g. inflammatory-dependent ones.
Atherosclerosis and RA disease are processes that take place over time, like the effects of the risk factors assumed to influence them. The previous, mostly cross-sectional studies may have limited ability to estimate the temporal relationships of change in exposure variables over time. It should be emphasized that single, non-cumulative measurements of apolipoproteins were not predictive of carotid outcomes in our study. The results reinforce the need of assessment over time to find predictors of subclinical atherosclerosis.
The important limitations of the study are the lack of a control group and the fact that carotid assessment was not performed at the study inclusion. Further, we did not have any information about CV complications during the follow-up. Thus, although we adjusted for known confounders at baseline and available ones throughout the study, our results may still have been affected by developing comorbidities, e.g. hypertension. A few subjects were set on lipid-lowering medication at the end of the study, which we assume as too short a period to affect the results. Besides, traditional lipids were not analysed.
To summarize, the present results indicate that beyond established CV risk factors apolipoproteins and IgM anti-PC may be of importance in RA-related atherosclerosis and could have implications for CV risk stratification algorithms. In addition, decreasing anti-PC but increasing oxLDL levels despite normalization of formal disease activity measures could reflect undertreated or unrecognized low-grade inflammation with potential influence upon both progression of atherosclerosis and RA disease per se. Further studies on the clinical issues of our findings are warranted.
Rheumatology key messages
. ApoA1 levels over time are negatively, while apoB and apoB/apoA1 ratio are positively, associated with carotid atherosclerosis in RA. . Low levels of atheroprotective anti-PC are associated with carotid plaque occurrence in RA.
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